Bone marrow disorder

This study looked at whether the HPV vaccine works in girls aged 9 to 17 who are taking medicines that weaken their immune system, such as after an organ transplant or for diseases like lupus. The goal was to see if their bodies produce enough antibodies to protect against HPV. T…

This study looks at the long-term safety of imatinib, a daily pill for certain cancers like GIST and CML. It includes 250 patients who were already benefiting from imatinib in a previous Novartis trial and continue taking it. The main goal is to track side effects over time, with…

This early-phase trial tested whether giving patients their own natural killer (NK) cells, boosted by the drug bortezomib, is safe for treating advanced cancers like leukemia, lung, and pancreatic cancer. Thirty-five adults whose cancers had not responded to standard treatments r…

This study tested a program to help people with opioid use disorder stay on their medication after being hospitalized for serious infections like endocarditis or bone infections. Forty adults took part to see if the program was practical and helpful. The goal is to improve long-t…

This study tests a new drug, AZD9829, in people with blood cancers that have come back or not responded to other treatments. The drug targets a protein called CD123 found on cancer cells. The main goals are to find a safe dose and check for side effects. About 56 adults will take…

This study tests whether giving full-strength chemotherapy (either CPX-351 or a combination called CLAG-M) can help medically less-fit adults with acute myeloid leukemia live longer and achieve remission. About 60 participants will receive one of the two treatments. The goal is t…

This study tests a drug called FT-2102 (olutasidenib) in people with acute myeloid leukemia or myelodysplastic syndrome whose cancers have a specific IDH1 gene mutation. The drug is given alone or combined with standard chemotherapy drugs (azacitidine or cytarabine). The goal is …

This study looked at whether taking oral azacitidine (Onureg) as maintenance therapy can help older adults with acute myeloid leukemia (AML) stay in remission longer after treatment with CPX-351 chemotherapy. The study included 100 patients aged 65 and older who had achieved remi…

This study tested a chemotherapy drug called CPX-351 in 59 adults aged 60 to 75 with a high-risk form of acute myeloid leukemia (AML). The goal was to see how well it could put the cancer into remission. Participants received the drug through an IV, and some also had a stem cell …

This phase III trial tests whether the drug tipifarnib can prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. Participants include adults over 60 in first remission, those in second or later remission, or those who achieved remission a…

This phase 3 trial is testing whether a combination of three drugs—azacitidine, venetoclax, and ATRA—can safely and effectively treat adults newly diagnosed with acute myeloid leukemia (AML). The drugs work together to stop cancer cell growth by demethylating DNA, promoting cell …

This study tested a daily pill called E7820 in 12 adults with relapsed or treatment-resistant acute myeloid leukemia, myelodysplastic syndromes, or chronic myelomonocytic leukemia. All participants had specific mutations in splicing factor genes. The goal was to see if the drug c…

This study tested the drug RAD001 (everolimus) in 29 patients with relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and myelofibrosis. The goal was to find the safest highest dose and see if it helps control the disease. It was a small early-phase trial at a singl…

This phase 2 trial is testing whether a combination of two drugs, venetoclax and azacitidine, can effectively treat adults aged 18 to 59 who have been newly diagnosed with acute myeloid leukemia (AML) and have not yet received any treatment. Participants take both drugs in cycles…

This study tested a drug called fedratinib in 25 adults with rare blood cancers (MDS/MPN and CNL). The goal was to see if the drug could shrink the spleen and improve blood counts. While not a cure, the treatment aims to control the disease and reduce symptoms.

This study looked at the safety and effectiveness of a drug called asciminib in 85 Indian adults with a specific type of leukemia (Ph+ CML-CP). Some participants had a genetic mutation (T315I) that can make treatment harder, while others had already tried two or more other drugs.…

This early-phase trial tested whether adding the drug uproleselan to standard chemotherapy (cladribine and low-dose cytarabine) could help people with treated secondary acute myeloid leukemia (AML). Secondary AML is a type of leukemia that develops after treatment for another bon…

This study tested a new formulation of two chemotherapy drugs (CPX-351) in 56 adults with newly diagnosed acute myeloid leukemia (AML) who were at high risk of not responding to standard treatment. The goal was to find the best dose and see how well it worked to stop cancer cells…

This study tested a combination of three drugs (decitabine, venetoclax, and ponatinib) in 20 adults with a rare, aggressive leukemia called Philadelphia chromosome-positive acute myeloid leukemia or chronic myelogenous leukemia in blast phase. The goal was to see if the drugs cou…

This study tested a new drug called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. In the first part, the drug was given alone to find the safest dose. In the second part, it was given with or without another drug (ruxolitinib) to see if it…

This study tested whether adding a drug called oblimersen to standard chemotherapy (daunorubicin and cytarabine) helps older adults (60+) with untreated acute myeloid leukemia live longer or achieve remission. About 500 participants were randomly assigned to receive chemo with or…

This early-phase study tested a new drug called TQ05105 in 79 adults with certain blood cancers (myeloproliferative neoplasms). The main goals were to find the safest dose and understand side effects. The drug works by blocking a protein (JAK2) that can cause abnormal blood cell …

This study tested a new way to treat blood cancers like leukemia in 16 adults who did not have a standard bone marrow donor. Doctors used a single unit of cord blood that was grown in a lab to increase the number of stem cells before transplant. The goal was to see if this method…

This study tested a new drug called TQ05105 in 107 people with moderate to high-risk myelofibrosis, a rare bone marrow disorder that often causes an enlarged spleen. The goal was to see if TQ05105 could shrink the spleen better than the standard drug hydroxyurea. Participants too…

This large phase III trial tested whether adding the drugs bortezomib and sorafenib to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) live longer without the cancer returning. Over 1,600 participants took part. The study focused on patients w…

This phase 2 trial tested a combination of intravenous busulfan, etoposide, and low-dose total-body irradiation before a donor stem cell or bone marrow transplant in 30 patients with advanced leukemia or myelodysplastic syndromes. The goal was to see how well this regimen control…

This study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemo…

This study tested a new treatment for adults with a high-risk form of acute promyelocytic leukemia (APL). The experimental therapy combined arsenic trioxide, ATRA, and a low dose of idarubicin, aiming to improve survival and reduce side effects compared to the standard chemothera…

This phase 2 trial tested whether certain biomarkers in bone marrow can predict how well patients with high-risk acute myeloid leukemia (AML) respond to treatment with sirolimus plus standard chemotherapy (MEC). The study enrolled 39 adults with AML that was hard to treat or had …

This early-phase trial tested a drug called ONC-201 in 20 people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who had recently received a stem cell transplant. Participants took the drug by mouth once a week for a year to see if it was safe and co…

This study tested whether adding the drug tocilizumab to standard care could reduce the risk of graft-versus-host disease (GVHD) after a cord blood transplant in adults with blood cancers. GVHD is a serious complication where donor cells attack the patient's body. Tocilizumab blo…

This phase 2 trial tests whether a combination of clofarabine and intermediate-dose cytarabine (CLARA) works better than high-dose cytarabine (HDAC) alone as consolidation therapy for younger adults (18-60) with newly diagnosed acute myeloid leukemia (AML). After initial remissio…

This study looked at 31 adults with chronic myeloid leukemia (CML) whose cancer came back after they stopped taking imatinib. They were given nilotinib, a more powerful targeted therapy, to see if it could make their cancer undetectable again and allow them to stop treatment once…

This study tested a three-drug combination (navitoclax, venetoclax, and decitabine) in 6 adults with high-risk myelodysplastic syndrome (MDS) that came back or didn't respond to standard therapy. The goal was to find the safest dose and see if the combo could shrink or control th…

This early-phase study tested a combination of three chemotherapy drugs (CPX-351 and gemtuzumab ozogamicin) in children whose acute myeloid leukemia (AML) had come back or didn't respond to standard treatment. The main goals were to find the best dose and check for side effects. …

This study looked at 220 adults with chronic myeloid leukemia who had been in deep remission for at least two years while taking imatinib. Researchers wanted to see if stopping the drug would cause the cancer to come back. They found that many patients stayed in remission after s…

This early-phase study tested a new drug called TGR-1202 combined with the standard drug ruxolitinib in 60 people with myelofibrosis or polycythemia vera. The goal was to see if the combination is safe and tolerable. Participants either had not responded well to ruxolitinib alone…

This study tested a new drug called S65487, which blocks a protein that helps leukemia cells survive, combined with the standard drug azacitidine. The trial included 57 adults with untreated acute myeloid leukemia who were not healthy enough for intensive chemotherapy. Researcher…

This study tested a new clinic that sees emergency room patients the next day for conditions like pneumonia, heart failure, and kidney injury. The goal was to avoid hospital stays and improve patient care. About 570 adults took part, and researchers measured how many days they we…

This early-phase study tested whether adding two targeted drugs, gemtuzumab ozogamicin and midostaurin, to standard chemotherapy is safe for people with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) that has a FLT3 mutation. The trial enrolled 21 adults and a…

This phase 1 trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 29 patients whose acute myeloid leukemia or myelodysplastic syndrome came back or did not respond after a donor stem cell transplant. The goal was to find the safest dose and see if the drugs could he…

This study tested a combination of three drugs (low-dose cytarabine or azacitidine, plus venetoclax and quizartinib) in 113 adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who were not eligible for standard chemotherapy. The goal was to quickly control …

This early-phase study tested a new drug called siremadlin added to two existing drugs (venetoclax and azacitidine) for adults with acute myeloid leukemia (AML) who are too frail for standard chemotherapy. The study included 14 people whose cancer did not respond well to initial …

This phase 2 study tested an oral drug called bomedemstat in 20 adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. The main goal was to see if the drug could safely lower red blood cell levels enough to avoid routine blood removal (phlebotomy…

This study tested an experimental pill called Bomedemstat in 73 people with essential thrombocythemia, a rare blood condition causing too many platelets. Participants had already tried at least one standard treatment without success. The main goals were to check safety and see if…

This study tested whether an oral medication (CC-486) could help elderly patients with a serious blood disorder called myelodysplastic syndrome (MDS) maintain their improvement after initial injectable treatment. Eleven patients who had responded to injectable azacitidine switche…

This early-stage study tested a new drug called LYT-200 in 101 adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) had come back or stopped responding to treatment. The main goals were to check the drug's safety and find the right dose. While not…

This early-phase trial tested a combination of two drugs, enasidenib and cobimetinib, in just 3 patients with a specific form of acute myeloid leukemia (AML) that had come back or didn't respond to treatment. The goal was to see if the combination was safe and to find the best do…

This early-stage trial tested an oral drug called NTX-301 in 22 adults with certain blood cancers (MDS, AML, or CMML) that had not responded to prior treatments. The main goal was to check safety and find the right dose. Researchers also looked for signs that the drug might help …

This study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regi…

This study tested a new approach for children and adults whose acute myeloid leukemia (AML) came back after a stem cell transplant. Researchers gave patients a special type of immune cell called cytokine-induced memory-like natural killer (CIML NK) cells, along with donor immune …

This phase 2 trial tested whether adding asciminib to the standard drug imatinib helps people with chronic myeloid leukemia (CML) achieve deeper remission. 104 adults who had been on imatinib for at least a year without reaching very low cancer levels were randomly assigned to ad…

This early-phase study tested a two-drug combination (pevonedistat plus decitabine) in 12 people with high-risk acute myeloid leukemia (AML), including those who had relapsed or couldn't tolerate standard chemo. The main goal was to find the safest dose and identify side effects.…

This study tested the drug eltrombopag in 34 people with moderate aplastic anemia, a condition where the bone marrow doesn't make enough blood cells. Eltrombopag is a pill that mimics a natural protein to stimulate blood cell production. Researchers measured whether it safely imp…

This study tested whether adding the antibiotic rifampin to standard treatment helps prevent amputations in diabetic patients with foot bone infections. Over 800 veterans participated, receiving either rifampin or a placebo for six weeks. The goal was to see if rifampin improves …

This early-phase trial tested the drug enasidenib in 17 people with low-risk myelodysplastic syndrome or a related leukemia who had anemia and did not have a specific gene mutation. The goal was to see if the drug could safely improve red blood cell counts and reduce the need for…

This study looked at whether giving the antibiotic vancomycin helps cancer patients who have diarrhea and a positive screening test for C. difficile but a negative toxin test. Only 9 patients were enrolled, far fewer than planned. Researchers measured changes in C. difficile leve…

This study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…

This study tested a new drug, crenolanib, against the standard drug midostaurin in adults with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). All 214 participants received standard chemotherapy and, if eligible, a bone marrow transplant, plus one of the two…

This study tested whether a combination of two drugs, venetoclax and azacitidine, can help adults with acute myeloid leukemia (AML) stay in remission after initial chemotherapy. The goal was to find the right dose and see if it safely delays the cancer from coming back. The study…

This study tested a combination of two drugs, azacitidine and venetoclax, in 42 elderly patients (age 60+) with newly diagnosed acute myeloid leukemia (AML) who could not have standard chemotherapy. The treatment was given as an initial 'induction' phase, followed by a 'maintenan…

This study tested whether adding the drug crenolanib to standard chemotherapy helps adults up to age 75 with a hard-to-treat form of acute myeloid leukemia (AML) that has a specific genetic change (FLT3 mutation). Participants received either crenolanib or a placebo alongside che…

This study tested a combination of two drugs, fedratinib and nivolumab, in 30 adults with myelofibrosis whose disease no longer responded well to standard JAK-inhibitor treatment. The goal was to see if the combination could shrink the spleen, improve symptoms, or reduce the need…

This study tested whether eating less fat and more fiber can reduce the chance of a repeat Clostridioides difficile infection in cancer patients. Eight participants with leukemia, lymphoma, or other cancers followed a specific diet. Researchers tracked diarrhea and measured C. di…

This study tested a personalized geriatric optimization plan (GO!) in 30 adults aged 60 and older who were getting a donor stem cell transplant for blood cancers or bone marrow failure. The plan included tailored advice on diet, sleep, activity, and medications to improve physica…

This study tested a drug called GO-203-2C, which targets a protein (MUC1) found on cancer cells while sparing healthy cells. It was given alone or with another drug (decitabine) to 33 adults with acute myeloid leukemia that had returned or not responded to treatment. The main goa…

This early-stage study tested whether adding a drug called BMS-986004 to standard immune-suppressing medicine could help prevent acute graft-versus-host disease (GVHD) in 45 adults with blood cancers or disorders receiving a stem cell transplant. GVHD occurs when donor immune cel…

This study tested a new treatment called CTX131 for adults with certain blood cancers (T-cell lymphoma, B-cell lymphoma, or acute myeloid leukemia) that had returned or stopped responding to standard therapy. CTX131 uses a patient's own immune cells, modified with CRISPR gene edi…

This study looked at 124 adults with chronic myeloid leukemia (CML) who had been on the drug nilotinib for at least 3 years and had very low levels of cancer. First, researchers tested if lowering the nilotinib dose by half for a year could help patients stop treatment entirely. …

This study tested whether adding pacritinib to standard immune-suppressing drugs (sirolimus and tacrolimus) could prevent graft-versus-host disease (GVHD) in 40 patients receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the recipient's …

This phase II trial tested whether adding the drug itacitinib to standard medications (tacrolimus and sirolimus) can better prevent graft-versus-host disease (GVHD) in 59 patients with blood cancers receiving donor stem cell transplants. GVHD occurs when donor immune cells attack…

This phase 2 trial looked at whether giving a JAK inhibitor (ruxolitinib) before a donor stem cell transplant helps people with myelofibrosis. The study enrolled 61 patients with primary or secondary myelofibrosis. The goal was to see if this approach improves survival and reduce…

This study tested a combination of two drugs, ruxolitinib and azacytidine, in 121 people with myelofibrosis or related blood cancers. The goal was to see if the combo could shrink tumors or improve blood counts. While the treatment aims to control the disease, it is not a cure, a…

This study tested the antibiotic omadacycline in 42 hospitalized adults with diabetic foot infections, some with bone infection. The goal was to see if it causes fewer kidney problems and gut infections compared to standard antibiotics. Researchers compared results to a group of …

This study tested a new method of cord blood transplantation in 13 children and young adults with high-risk myeloid cancers. The approach uses a molecule called UM171 to grow more stem cells from a single cord blood unit, aiming to speed up recovery and reduce complications. Earl…

This phase 2 trial tested whether adding the targeted drug quizartinib to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) that does not have a FLT3 mutation. 273 patients were randomly assigned to receive either quizartinib or a placebo alongs…

This study tested a new way to prepare patients with relapsed or hard-to-treat acute leukemia for a donor stem cell transplant. It combined a precise form of radiation therapy (IMRT) with two chemotherapy drugs (etoposide and cyclophosphamide) before the transplant. The goal was …

This study tested whether a hydrochloric acid lock can help treat central line infections in 212 cancer and blood disease patients. The acid solution was placed in the line for 10 minutes, repeated three times, alongside standard antibiotics. The goal was to see if it reduces tre…

This study tested whether adding the experimental drug navitoclax to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. The main goal was to see if the combination could shrink an enlarged spleen by at le…

This study tested a new way to prepare cord blood for transplant in 30 people with high-risk leukemia or myelodysplasia. The cord blood was treated with a molecule called UM171 to help it grow more stem cells. The goal was to see if this approach is safe and helps patients recove…

This study looked at whether children with cancer and a fever caused by low white blood cells can safely stop antibiotics earlier than usual. 55 children took part, and half stopped antibiotics once their fever was gone for 48 hours, while the other half continued until their whi…

This study tested the drug asciminib in 199 adults with chronic myeloid leukemia (CML) whose cancer was not well controlled after trying at least two other targeted therapies. The main goal was to see how many patients achieved a major molecular response (a key sign of disease co…

This phase 2 trial tested a two-step stem cell transplant approach for 47 patients with high-risk blood cancers like leukemia and lymphoma. The method uses the drug cyclophosphamide to lower the chance of graft-versus-host disease (GVHD), a common complication. The goal was to se…

This study tested three different starting doses (45 mg, 30 mg, and 15 mg daily) of the drug ponatinib in 283 adults with chronic phase chronic myeloid leukemia (CML) that had stopped responding to other treatments or had a specific genetic mutation (T315I). The main goal was to …

This early-phase study tested a combination of two drugs, venetoclax and omacetaxine, in 6 adults with acute myeloid leukemia (AML) whose cancer had stopped responding to venetoclax-based treatments. The main goal was to find the safest dose of omacetaxine when given with venetoc…

This early-phase trial tested a new type of stem cell transplant called a microtransplant in 25 people with myeloid blood cancers (like leukemia) who were too old or frail for a standard transplant. Unlike a regular transplant, this one used stem cells from a partially matched fa…

This phase 2 trial tested a combination of treosulfan, fludarabine, and rabbit antithymocyte globulin before a bone marrow transplant in 40 people with bone marrow failure diseases like Diamond-Blackfan anemia and Shwachman-Diamond syndrome. The goal was to see if this conditioni…

This study tested whether matching chemotherapy intensity to a patient's genetic risk and overall health could improve outcomes for older adults (60+) with acute myeloid leukemia. 75 participants received either standard intensive or lower-intensity chemo based on their individua…

This early-phase trial tested a combination of two drugs, ibrutinib and lenalidomide, in 4 patients with myelodysplastic syndrome (MDS) who had not responded to or could not tolerate standard treatments. The main goal was to find the safest dose and identify side effects. While t…

This pilot study tested a combined bone marrow and kidney transplant from a partially matched family donor in 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions at once and possibly reduce the need for lifelong anti-rejection dr…

This early-phase trial tested a cancer vaccine (CDX-1401) along with an immune booster, chemotherapy, and an immunotherapy drug in 8 people with myelodysplastic syndrome (MDS) or low-blast acute myeloid leukemia (AML). The goal was to see if the combination is safe and helps the …

This Phase 3 trial tested a special cord blood product called NiCord (omidubicel) against standard cord blood transplants in 125 people with blood cancers like leukemia and lymphoma. The goal was to see if NiCord helps the body rebuild its infection-fighting cells faster. Researc…

This early-phase trial tested a new treatment for people with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (AML) who had not responded to prior therapy. The treatment involved giving specially prepared donor immune cells (with CD8 cells removed to reduce ris…

This early-phase study tested a new cell therapy called LILRB4 STAR-T cells in one person with monocytic leukemia, a type of blood cancer. The goal was to see if the treatment is safe and can reduce cancer cells in the bone marrow. Researchers monitored side effects like cytokine…

This early-phase study tested a new treatment using lab-grown immune cells (iPSC NK cells) in 2 adults with hard-to-treat acute myeloid leukemia (AML) or signs of remaining disease after treatment. The main goal was to check safety and find the right dose. Researchers also looked…

This study looked back at 320 children with acute myeloid leukemia (AML) who received one of two chemotherapy regimens between 2005 and 2015. The newer approach used a risk-based strategy and more intensive chemotherapy. Researchers compared survival, relapse, and remission rates…

This study looked at how adults with a specific type of acute myeloid leukemia (AML) who cannot receive standard chemotherapy feel and function while taking a combination of ivosidenib and azacitidine. The main goal was to measure quality of life using questionnaires, along with …

This early-phase study tested a new cell therapy called RD13-02 in just 2 people with relapsed or refractory CD7-positive blood cancers (like T-cell leukemia or lymphoma). The treatment uses specially engineered immune cells to attack cancer cells. The main goals were to check sa…

This study tested a three-drug chemotherapy combination (cladribine, homoharringtonine, and cytarabine) in 65 adults under 60 with newly diagnosed acute myeloid leukemia (AML). The goal was to see how well it wiped out leukemia cells and how safe it was. Results tracked complete …

This early-stage trial tested the safety and best dose of flotetuzumab, an antibody drug, in 13 patients with advanced blood cancers that had come back or stopped responding to treatment. The drug works by blocking cancer cell growth. The main goal was to see what side effects oc…

This early-stage study tested an experimental drug called KPT-9274 in 16 adults whose acute myeloid leukemia (AML) had come back or did not respond to standard treatments. The main goal was to find a safe dose and check for side effects. The study is now complete, and results wil…

This early-stage study tested a new drug called PRT2527, alone or with other cancer drugs (zanubrutinib or venetoclax), in 86 people with various blood cancers that had returned or stopped responding to standard treatments. The main goals were to check safety, find the best dose,…

This early-phase study tested an experimental oral drug called LP-108, given alone or with another drug (azacitidine), in 32 adults with blood cancers (MDS, CMML, or AML) that returned or didn't respond to prior therapy. The main goals were to find the safest dose and understand …

This study looked at using a surgical approach from the back (posterior) to treat bacterial infections of the spine. 47 patients underwent the procedure, which involved removing infected tissue and stabilizing the spine. The researchers found no major complications and reported s…

This study tested a drug called navitoclax, either alone or added to the standard drug ruxolitinib, in 191 people with myelofibrosis. The main goal was to see if the treatment could shrink the spleen by at least 35% after 24 weeks. The trial also looked at whether it could reduce…

This study tested a combination of six drugs (venetoclax plus CACAG regimen) against the standard '3+7' chemotherapy in 200 adults newly diagnosed with acute myeloid leukemia. The goal was to see if the new combo leads to more complete remissions after one treatment course. The t…

This early-phase trial tested a combination of two chemotherapy drugs, bortezomib (Velcade) and lenalidomide (Revlimid), in 22 adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) had returned after a stem cell transplant. The main goal was to find the safe…

This study tested whether the drug dasatinib can control chronic myeloid leukemia (CML) in its early chronic phase. 150 adults with newly diagnosed CML took dasatinib, and researchers measured how many achieved a major molecular response (very low levels of cancer genes) after 12…

This early-phase study tested the drug regorafenib in 16 adults with advanced blood cancers like acute myeloid leukemia (AML) that had stopped responding to other treatments. The main goal was to find the safest dose and see how the drug affects cancer-related cell signals. While…

This early-phase trial tested the safety of giving donor natural killer (NK) cells to 19 patients with acute myeloid leukemia that had returned or not responded to treatment. Patients first received chemotherapy, then up to six infusions of specially grown NK cells from a donor. …

This study tested whether a low dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (GVHD) — a common and serious complication where donor cells attack the patient's body. The trial involved 35 adults with various blood dis…

This study tested whether the antibiotic levofloxacin can prevent fevers and infections in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who are receiving the chemotherapy drug azacitidine. Infections are a major risk for these patients. The trial ran…

This study tested the drug dasatinib in 68 adults with several types of blood and bone marrow disorders, including certain leukemias, myelofibrosis, and mastocytosis. The goal was to see if dasatinib could help control the disease and to check its safety. Participants took dasati…

This study tested whether brushing teeth is safe for patients with prolonged aplasia (low blood cell counts) after intensive chemotherapy. Currently, many hospitals only allow mouthwash to avoid bleeding and infection. The trial compared brushing with an extra-soft toothbrush plu…

This study tested a new drug called VIC-1911 added to standard medications to prevent graft-versus-host disease (GVHD) in 16 adults with blood cancers receiving a stem cell transplant. The goal was to find a safe and effective dose that reduces GVHD and relapse. Results are still…

This study tested whether adding ready-made natural killer (NK) cells from a donor to a standard stem cell transplant could safely reduce the chance of cancer returning in people with high-risk myeloid cancers like acute myeloid leukemia, myelodysplastic syndrome, and chronic mye…

This study tested whether adding the drug abatacept to standard medications (calcineurin inhibitor and methotrexate) could better prevent severe acute graft-versus-host disease (aGVHD) after a stem cell transplant from an unrelated donor. A total of 186 participants aged 6 and ol…

This phase II trial tested two drugs—sirolimus and azacitidine—in 57 people with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that had come back or didn't respond to standard treatment. The goal was to see if the combination could shrink or control the…

This study looked at how well the drug Venetoclax works for adults with acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 120 patients in Switzerland and Austria took Venetoclax pills daily as part of their normal care. Researchers tracked …

This study tested a stem cell transplant from half-matched (haploidentical) family donors for 34 people with various blood cancers. Patients received a reduced-intensity conditioning regimen of fludarabine, melphalan, and total body irradiation before the transplant. The goal was…

This study tested two different chemotherapy drugs (Treosulfan and Busulfan) given before a stem cell transplant in 106 children with serious non-cancer diseases like immune disorders, metabolic diseases, blood disorders, and bone marrow failure. The goal was to see which drug le…

This study tested a new drug called gilteritinib against standard chemotherapy in 371 adults with a type of acute myeloid leukemia (AML) that has a specific genetic change (FLT3 mutation) and has either come back or not responded to initial treatment. The goal was to see if gilte…

This phase 2 trial tested a treatment for adults with acute myeloid leukemia (AML) in first remission. Patients received high-dose chemotherapy and radiation to kill cancer cells, followed by an autologous stem cell transplant (using their own stem cells) to restore blood cell pr…

This study tested adding a drug called thiotepa to the usual chemotherapy given before a donor stem cell transplant for people with leukemia. The goal was to see if this stronger mix could help more patients stay cancer-free one year after the transplant. The study included 40 ad…

This study tested a drug called eltrombopag in 118 people with bone marrow failure who had a stem cell transplant. The goal was to see if the drug could help their platelet levels recover faster after the transplant. Platelets are blood cells that help stop bleeding, and slow rec…

This study looks at how safe and effective the oral drug venetoclax (Venclexta) is for adults with acute myeloid leukemia (AML) when used in everyday medical practice. About 150 people in South Korea took the drug as prescribed by their doctor for up to 7 months. Researchers trac…

This early-phase trial tested a combination of two drugs—veliparib and temozolomide—in 66 adults with relapsed or refractory acute leukemias. Veliparib blocks a DNA repair enzyme, while temozolomide damages cancer cell DNA. The goal was to find the safest dose and check for side …

This study tested an oral liquid form of arsenic trioxide (SDK001) in 12 people with acute promyelocytic leukemia (APL). Researchers compared how well the body absorbs the oral drug versus the standard IV version, and whether food or calcium supplements change absorption. The goa…

This phase 2 trial tested a daily pill called pemigatinib in 47 people with a rare type of blood cancer caused by a specific genetic change (FGFR1 rearrangement). The drug aims to shrink or eliminate cancer cells by blocking a faulty protein. Participants took the drug in cycles,…

This study looked at 50 patients who needed a stem cell transplant from a partially matched donor but had antibodies that could attack the donor cells. Before transplant, they received a blood purification treatment called protein A immunoadsorption to remove those antibodies, so…

This early-phase trial tested replacing the standard drug cyclophosphamide with bendamustine after a half-matched bone marrow transplant in 50 patients with various blood cancers. The goal was to see if this change could reduce side effects like graft-versus-host disease while st…

This completed Phase 1 trial tested a new drug called IkT-001Pro in 64 healthy adults aged 18 to 55. The goal was to see if it works like the standard CML drug imatinib in the body. Participants took single doses of both drugs at different times to compare how they are absorbed a…

This study tested a drug called guadecitabine combined with donor lymphocyte infusions in 55 patients whose acute myeloid leukemia or myelodysplastic syndrome came back after a stem cell transplant. The goal was to see if the drug could help the donor immune cells fight the cance…

This study tested the drug ivosidenib as a maintenance therapy for people with IDH1-mutant blood cancers (like AML) after a stem cell transplant. The goal was to find the safest dose and see if it could help prevent the cancer from coming back. 18 participants took the pill daily…

This study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cance…

This study tested whether adding pevonedistat to the standard drug azacitidine helps people with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or low-blast acute myeloid leukemia live longer without their disease getting worse. About 454 adults took part…

This study tested whether adding a drug called pevonedistat to the standard two-drug combination (venetoclax and azacitidine) helps adults recently diagnosed with acute myeloid leukemia (AML) who are too frail for intensive chemotherapy. About 164 participants received either the…

This pilot study tested a liposomal form of the chemotherapy drug vincristine (Marqibo) combined with standard UK ALL R3 chemotherapy in 29 children, adolescents, and young adults with relapsed acute lymphoblastic leukemia. The main goal was to see if it was safe and tolerable at…

This phase 2 trial tested whether adding lenalidomide to standard MEC chemotherapy helps adults with relapsed or refractory acute myeloid leukemia (AML) achieve remission. 41 participants received the combination. The main goal was to see how many achieved complete remission. Thi…

This study tested a new drug called asciminib in 56 adults with chronic myeloid leukemia (CML) whose cancer had not responded well to other treatments. The drug is taken as a pill and aims to control the disease. The main goal was to check safety and side effects over 24 weeks, w…

This early-phase study tested whether adding two drugs (decitabine and vorinostat) before and during standard chemotherapy (FLAG) is safe for children and young adults up to age 25 with acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal was to…

This phase 1 study tested the drug enasidenib as a maintenance therapy after a stem cell transplant in 23 people with IDH2-mutant acute myeloid leukemia or chronic myelomonocytic leukemia. The goal was to find the safest dose and see how well patients tolerated it. Enasidenib wor…

This early-stage trial tested a combination of two drugs, pegcrisantaspase and venetoclax, in 27 adults whose acute myeloid leukemia had come back or not responded to standard treatments. The main goal was to find safe doses and check for side effects. Researchers also looked at …

This early-stage study tested a new drug called JNJ-74856665 in 153 people with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). The main goals were to find safe doses and check for side effects when given alone or with oth…

This study tested whether a combination of two drugs, cyclophosphamide and abatacept, could lower the risk of chronic graft-versus-host disease (GVHD) after a stem cell transplant in people with high-risk blood cancers. GVHD happens when donor cells attack the patient's body. The…

This study tested whether adding the drug venetoclax to a low-dose chemotherapy (LDAC) helps people with acute myeloid leukemia (AML) live longer. It included 211 adults aged 75+ or 18–74 with health issues that prevent them from receiving strong chemotherapy. The main goal was t…

This study tested whether the drug palifermin could make stem cell transplants safer and reduce chronic graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Thirty-four adults with blood cancers received palifermin before transplan…

This early-phase trial tested a new drug called flonoltinib maleate in 31 people with myeloproliferative neoplasms (MPNs), a group of bone marrow cancers. The main goals were to check safety, find the right dose, and see how the body processes the drug. Researchers hope this drug…

This study tested a new drug called liposomal annamycin combined with standard chemotherapy (cytarabine) in 22 adults with acute myeloid leukemia (AML). The goal was to find the safest dose and see if the combination can control the disease. Participants had either newly diagnose…

This early-phase study tested a new treatment called WU-NK-101 in 9 adults with acute myeloid leukemia (AML) that returned or didn't respond to standard therapy. The goal was to check safety and find the best dose. Participants received immune cells designed to attack cancer. Thi…

This study tested whether adding a second drug (pegylated interferon) to the standard leukemia medication nilotinib helps people with newly diagnosed chronic myeloid leukemia (CML) achieve a deeper molecular response faster. About 200 adults under 65 with early-stage CML took par…

This study looked at whether people with chronic myeloid leukemia (CML) who had a good response to the drug nilotinib could switch to imatinib to maintain that response. The goal was to see if imatinib could keep the cancer under control while being easier to take and less expens…

This study compared a generic azacitidine tablet to the brand-name drug Onureg in 32 adults with acute myeloid leukemia (AML) who are in remission. Participants took a single dose of each drug under fasting conditions to see if the generic version is absorbed similarly. The goal …

This study tested a combination of two drugs, azacitidine and venetoclax, in 40 adults aged 45 to 65 with newly diagnosed acute myeloid leukemia (AML). The goal was to see how safe and effective the combo is at shrinking the cancer. Participants received the drugs in 28-day cycle…

This study looks at the long-term safety of bomedemstat, an oral drug, in 81 people with myeloproliferative neoplasms (MPNs) like essential thrombocythemia and primary myelofibrosis. Participants had already taken bomedemstat in a prior study. Researchers tracked side effects, sp…

This Phase 2 study tested a drug called P1101 (ropeginterferon alfa-2b) in 29 Japanese adults with polycythemia vera (PV), a blood disorder that causes too many red blood cells. The participants were people for whom standard treatments are hard to use, such as younger patients or…

This phase 3 study tested a new drug, gilteritinib, combined with azacitidine for people with a specific type of acute myeloid leukemia (AML) that has a FLT3 mutation. The participants were adults who could not receive standard intensive chemotherapy. The study compared the combi…

This study looked at whether people with chronic myeloid leukemia (CML) who have done very well on the drug nilotinib can safely stop taking it. 215 patients who had been on nilotinib for at least two years and had very low levels of cancer cells were enrolled. The main goal was …

This early-phase trial tested adding the cholesterol drug pitavastatin to the standard leukemia medicine venetoclax in 6 people with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML). The main goal was to find a safe dose and check for side effects. Researchers a…

This early-phase study tested the safety of a drug called flotetuzumab in 3 adults with acute myeloid leukemia (AML) that had returned after a stem cell transplant. The drug targets a protein on leukemia cells and was given as a continuous infusion. The main goal was to find a sa…

This study looked at whether people with chronic myeloid leukemia (CML) who had very low levels of cancer cells could safely stop taking the drug nilotinib (Tasigna). Participants had already been treated with imatinib (Gleevec) and then nilotinib for at least 3 years. The main g…

This study tested a drug called gilteritinib (Xospata) alongside standard chemotherapy in 97 people newly diagnosed with acute myeloid leukemia (AML), especially those with a FLT3 gene mutation. The first part aimed to find the safest dose, and the second part measured how many p…

This phase 2 study tested the drug itacitinib in 4 people with myelofibrosis (a bone marrow disorder) who had already tried other treatments like ruxolitinib or fedratinib. The main goals were to check safety and find the right dose, and to see if it could shrink an enlarged sple…

This study looked at whether certain proteins in saliva can help tell the difference between healthy gums, gingivitis (mild gum inflammation), and periodontitis (serious gum disease). Researchers collected saliva from 60 people and measured three specific biomarkers. The goal is …

This study tested a Turkish version of the Johns Hopkins In-Room Independence Scale, which measures a patient's ability to move, use the toilet, and think clearly while in their hospital room. Researchers worked with 100 adults who had conditions like stroke, Parkinson's, or ampu…

This study tested a non-invasive breathing technique (CO-rebreathing) to measure red blood cell mass in people with polycythemia, a condition with too many red blood cells. The goal was to see if it works as well as the standard radioactive test. Sixty adults took part, and the r…

This study tested whether quercetin, a natural substance found in some foods, could help prevent a type of mouth cancer in people with Fanconi anemia, a rare genetic condition that raises cancer risk. 48 participants took quercetin to see if it reduced certain cell changes linked…

This study looked at whether touch-massage can reduce anxiety in people with blood disorders (like leukemia or lymphoma) who are hospitalized in a sterile, isolated room. Sixty-two patients received three massage sessions, and researchers measured their anxiety levels before and …

This early-stage study looked at whether giving two standard chemotherapy drugs (cytarabine and daunorubicin) in a different way could be safer for the heart in adults newly diagnosed with acute myeloid leukemia (AML). Researchers used heart MRI scans to monitor for damage. The g…

This study tested whether adding a palliative care team to standard cancer care improves quality of life for people with acute myeloid leukemia (AML). 160 hospitalized patients with high-risk AML were randomly assigned to receive either usual oncology care or care that included a…

This study tested whether a mobile health program—including a Fitbit with movement reminders, coaching sessions, and a WhatsApp peer support group—could help 20 adolescents and young adults with acute lymphoblastic leukemia (ALL) reduce the time they spend sitting or lying down d…

This study looked at how satisfied people were with three different types of mouthguards (occlusal splints) for jaw joint and muscle pain (TMD). 27 adults who had jaw pain for at least 3 months and had never been treated for it tried one of the splints. The main goal was to see w…

This study looked at how common muscle and posture problems are in physiotherapy students and whether a special physiotherapy program could help. 44 students with back pain and muscle tightness received treatments like trigger point release, stretching, and joint mobilization. Th…

This study looked at whether music therapy can help reduce fatigue and improve certain blood test results in people with acute myeloid leukemia who are going through chemotherapy for the first time. Sixty adults took part, and researchers measured their fatigue levels and lab val…

This study looked at whether providing free blood transfusions to blood cancer patients would encourage them to enroll in hospice care earlier. Many patients delay hospice because they need transfusions for symptom relief, but hospices often cannot afford to provide them. The stu…

This study tested whether adding pain neuroscience education, motor imagery, and action observation to standard treatment (splint, exercises, counseling) helps people with chronic temporomandibular disorders (TMD). Fifty adults with jaw pain for at least 3 months participated. Th…

This completed study tested a new physical therapy program called deep sensory assisted rehabilitation in 40 people with multiple sclerosis. The program added exercises with a weighted vest (4-6 kg) to standard rehab, aiming to improve sensation, walking, and balance. Researchers…

This study tested a monthly online peer support group for young adults (ages 18-39) who had received a stem cell transplant. The group met for one hour over six months, led by a nurse and social worker. The goal was to see if the program was practical and helpful for reducing anx…

This study tested whether montelukast (Singulair), a common asthma drug, can reduce the number and severity of infusion reactions in people receiving monoclonal antibody treatments for blood disorders. Forty adults were given montelukast along with standard premedication before t…

This study looked at whether a structured physical therapy program before surgery could help an 11-year-old girl with a deformed upper arm bone. The girl had chronic bone infection that left her with shoulder deformity. Over 12 sessions, she received treatments like electrical ne…

This study tested two oral medications, aprepitant and hydroxyzine, to see which better reduces severe itching triggered by water contact in people with myeloproliferative neoplasms (a type of blood cancer). 63 participants who had persistent itching rated 5 or higher on a 10-poi…

This study looked at whether letting patients control their own sedation during arm surgery under regional anesthesia leads to higher satisfaction compared to having an anesthesiologist control it. 70 adults having upper limb orthopedic surgery were randomly assigned to either pa…

This study tested a web-based program to help children aged 8-17 with cancer adjust to returning to school. The program included modules for children, parents, teachers, and peers, focusing on communication, coping, and social skills. Twenty children participated, and researchers…

This study looked at whether early, regular visits from a palliative care team can improve quality of life for adults with acute leukemia that has returned. 49 patients were assigned to either receive this extra support or standard care. The team addressed physical, emotional, an…

This study looks back at medical records from a single hospital in Scotland to see how well the drug bosutinib works and how safe it is for people with chronic myeloid leukemia (CML) in everyday practice. Researchers will track blood cell counts, genetic responses, and side effec…

This study translated the Generic Functional Index, a questionnaire that measures how well people can do daily activities, into Turkish. Researchers tested it with 200 adults who have muscle or joint problems to see if it is accurate and reliable. The goal is to give Turkish-spea…

This early-phase trial tested whether adding atovaquone (a drug usually used to prevent pneumonia) to standard chemotherapy is safe and reaches effective levels in the blood. It involved 26 children and young adults (ages 1 month to 21 years) newly diagnosed with acute myeloid le…

This completed study from France examined whether a specific type of immune cell (innate CD8+ T cells) is linked to how quickly resistance mutations develop in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Researchers analyzed blood…

This study looked for a virus called HHV6 in the skin and blood of 37 adults with blood cancers who developed a rash during hospital stays. The goal was to see if the virus is linked to the rash, which could help doctors diagnose and treat the rash more effectively. The study is …

This completed study looked at blood vessel cells from 30 people with primary myelofibrosis, a rare bone marrow disorder. Researchers wanted to see if these cells act like stem cells that could be the origin of the disease. By growing the cells in the lab, they aimed to understan…

This study looked at how kidney function and race/ethnicity affect the drug treosulfan in 20 patients with AML or MDS getting a stem cell transplant. The goal was to find safe doses for those with kidney problems. It was a small, early-phase study that did not test a new treatmen…

This study looked at the tiny organisms (bacteria and fungi) living in the mouth and nose of children with leukemia or those getting a bone marrow transplant. Researchers wanted to see how these germ communities change during chemotherapy. The goal was to learn more, not to test …

This study looked at how often people with certain blood cancers or related conditions have an acquired deficiency of an enzyme called pyruvate kinase, which can cause anemia. Researchers took a single blood sample from 18 participants to measure enzyme activity and check for rel…

This study looked back at 621 children in Denmark who had chemotherapy for acute leukemia between 2008 and 2022. The goal was to find out how many got serious mold infections and what factors made it more likely. The results will help doctors better protect children during treatm…

This study tested a tool called UR-GOAL to help older patients with acute myeloid leukemia (AML), their caregivers, and their doctors communicate better and make decisions together. It involved 161 participants aged 60 and older. The goal was to see if the tool improved shared de…

This completed study followed 73 adults with bone or joint infections who needed antibiotics for at least 6 weeks. Researchers tracked how often side effects occurred, how severe they were, and whether they affected quality of life. The goal was to understand why some patients st…

This study looked at whether it is safe to lower the number of platelets needed before placing a central line (a special IV) in patients with blood disorders. Normally, patients get a platelet transfusion if their count is below 50, but this study tested a lower trigger of 10. Th…

This study looked at 308 people with myelodysplastic syndromes (MDS) who had a stem cell transplant. Researchers identified each patient's unique genetic mutations and then monitored those mutations in blood and bone marrow samples after transplant. The goal was to see if rising …

This study collected blood, bone marrow, skin, and cheek cell samples from 650 adults with acute leukemia, myelodysplastic syndromes, or myeloproliferative disorders. Researchers analyzed the samples to find genetic, epigenetic, and drug sensitivity patterns that might predict ho…

This pilot study tested a communication tool called UR-GOAL in 15 older adults (age 60+) with newly diagnosed acute myeloid leukemia (AML), along with their caregivers and doctors. The tool helps patients share their preferences and goals, so treatment decisions better match what…

This study tests whether measuring two substances in the blood—FLT3L and IL-6—during chemotherapy can help predict survival in people with acute myeloid leukemia (AML). Researchers will track 201 newly diagnosed AML patients across 25 French hospitals. The goal is to confirm that…

This study tested whether a telehealth program could help older patients (60+) with acute myeloid leukemia or myelodysplastic syndrome discuss and document their future medical wishes. Researchers enrolled 36 patients, caregivers, and clinicians to see if the program was easy to …

This study looked at how well two different capsule forms of TP-3654 are absorbed by the body and whether taking them with food changes absorption. It involved 24 healthy adults and was completed. The results will help design future studies for people with myelofibrosis, a bone m…

This study tested whether specially trained physiotherapists can safely diagnose and treat non-urgent muscle and joint pain in the emergency room, compared to standard care from doctors. 102 patients with back, neck, or shoulder pain were randomly assigned to either a physiothera…

This completed study collected real-world data from 112 adults in France with acute myeloid leukemia (AML) who were in remission and taking oral azacitidine as maintenance therapy. The goal was to describe patient characteristics, treatment patterns, and outcomes like relapse and…

This completed study enrolled over 2,100 people with or suspected of having myelodysplastic syndromes (MDS), a group of blood disorders. Researchers collected medical data, blood, and tissue samples over time to track how the disease develops and progresses. The goal was to creat…

This study looked back at medical records of 1,480 people with chronic-phase chronic myeloid leukemia (CML) treated in U.S. community oncology clinics between 2016 and 2022. Researchers examined which drugs were used, how doses were adjusted, and how well patients responded. The …

This completed study looked at bone marrow stem cells from 70 adults with acute myeloid leukemia (AML) who had a favorable genetic marker (NPM1 mutation). The goal was to understand why more than half of these patients still relapse despite having a good prognosis. Researchers an…

This study looked at levels of certain blood clotting proteins (antithrombin III, protein C, protein S, and D-dimer) in 60 people with acute leukemia and compared them to 30 healthy volunteers. The goal was to see if these proteins are different in leukemia patients. No treatment…

This completed study tested whether artificial intelligence and MRI scans could help automate the planning of total marrow irradiation, a type of radiation therapy given before a bone marrow transplant for blood cancers. Researchers aimed to reduce the 10-day planning time and be…

This study reviewed medical records of 355 people in Turkey with myelofibrosis (a type of bone marrow cancer) who were treated with the drug ruxolitinib for at least 3 months. Researchers collected information on patient demographics, disease characteristics, and how the drug was…

This study looked at 70 people—some with primary myelofibrosis and some healthy—to understand how certain immune cells called MDSCs fuel inflammation in this rare bone marrow disease. Researchers also checked how these cells change with treatment and whether they help form new bl…

This study looked at 1,753 patients needing a stem cell transplant for blood cancers or other serious blood disorders. Researchers compared two strategies: first searching for a matched unrelated donor, then trying an alternative donor if needed, versus going straight to an alter…

This study looked at whether people who inject opioids can safely finish a course of IV antibiotics at home instead of staying in the hospital. Ten participants received home antibiotic therapy along with addiction medication and support from a health coach and case manager. The …

This pilot study looked at ovarian tissue from 9 young women with acute myeloid leukemia who had it frozen to preserve fertility before a stem cell transplant. Researchers checked the frozen tissue for any leftover leukemia cells. The goal was to see if the tissue might be safe t…

This study looked at whether MRI scans can reliably find a torn disc in the jaw joint (temporomandibular joint). Researchers reviewed MRI images and medical records from 282 people to see how often disc tears occur and how they relate to pain, disc shape, and bone changes. The go…

This study examined tissue samples from 50 patients with staphylococcal bone and joint infections to see if bacteria can hide inside human cells. Researchers used special staining to detect intracellular staphylococci and identify which cell types they occupy. The goal was to bet…

This study looked at over 1,200 people in Denmark who had a stem cell transplant for blood diseases, some as far back as 1970. Researchers used detailed surveys to measure late effects and quality of life. The goal is to find out what medical and personal factors help survivors f…

This pilot study looked at 20 adults with acute myeloid leukemia (AML) who were not healthy enough for strong chemotherapy. They received a standard combination of azacitidine and venetoclax. Researchers measured venetoclax levels in the blood at several time points to see if tho…

This study looked at whether adding physical and occupational therapy consultations for adults getting a bone marrow transplant could improve outcomes like shorter hospital stays and fewer readmissions. Researchers compared data from before and after the therapy program was added…

This phase 1 trial in 40 healthy adults tests how TQ05105, a drug for myelofibrosis, interacts with other medications that affect liver enzymes. Participants take TQ05105 alone and then with either itraconazole or rifampicin to see how these drugs change TQ05105 levels in the bod…

This study tested a new drug called ZE46-0134 in 112 healthy adults to see if it is safe and how the body handles it. The drug is being developed for a type of blood cancer called AML. Since this was the first time the drug was given to people, the main goal was to check for side…

This study collected stool samples from 14 patients with bone or joint infections who were receiving long-term antibiotics injected under the skin. The goal was to build a biological sample bank for future research on how gut bacteria develop resistance to antibiotics. No treatme…

This completed study compared how well people with complex regional pain syndrome (CRPS), people with other muscle or bone pain, and healthy individuals can imagine movements. Researchers used a questionnaire called the MIQ-RS to measure motor imagery skills. The goal was to see …

This study looked at how the antifungal drug posaconazole affects blood levels of the cancer drug venetoclax in 15 adults with acute myeloid leukemia (AML) who were also receiving a hypomethylating agent (azacitidine or decitabine). The goal was to see how many patients reached s…

This completed study examined lung CT scans from 148 adults with blood diseases to identify common patterns of lung involvement. Researchers tracked how often certain radiological features appeared and counted complications. The goal was to better understand the range of lung iss…

This study observed 113 adults in Italy with acute myeloid leukemia (AML) linked to prior cancer therapy or bone marrow problems. All participants received Vyxeos liposomal as part of their normal care. Researchers tracked how many achieved complete remission without detectable d…

This study collected blood, saliva, stool, urine, and skin samples from 19 people with unknown or poorly understood immune system problems. The goal was to learn how different parts of the immune system work together. No treatments or drugs were tested. Participants were followed…

This study tested whether artificial intelligence (AI) can help doctors diagnose a rare blood cancer called acute promyelocytic leukemia (APL) more quickly and accurately. Ten doctors reviewed bone marrow samples with and without AI assistance. The goal was to see if AI improves …

This study looked at 126 people aged 60 and older who had a bone marrow transplant for blood cancers like leukemia or lymphoma. Researchers measured physical abilities, mental health, and stress levels before and after transplant to find traits that help people recover better. Th…

This study surveyed 116 adults with chronic pain at a rehabilitation clinic to understand how their pain beliefs, spiritual well-being, and attitudes toward complementary and alternative medicine are related. Participants filled out several questionnaires about their pain, mood, …

This study looked back at the medical records of 400 adults with a specific type of acute myeloid leukemia called core binding factor (CBF) leukemia. Researchers wanted to see how well current treatments work and what factors affect outcomes, such as genetic mutations and signs o…

This study looked at how 2,298 older adults with chronic myeloid leukemia (CML) were treated in everyday medical practice, using Medicare records. Researchers tracked which drugs patients took, how often they switched treatments, and how much healthcare they used. The goal was to…

This completed study looked at 552 adults with myeloproliferative neoplasms (MPN) who also had COVID-19. Researchers wanted to see how often these patients developed blood clots, like pulmonary embolism. The goal was to understand what factors make COVID-19 worse for people with …

This pilot study tested whether a combination of two drugs (G-CSF and plerixafor) could safely collect enough stem cells from the blood of children with Fanconi anemia for future gene therapy. Only 4 patients took part, and the main goal was to see if the cell collection process …

This completed study analyzed data from 249 adults with blood cancers like lymphoma and leukemia who received immunotherapy. The goal was to find markers—such as patient history or lab results—that could predict who will respond well and who might have severe side effects. By ide…

This study looked at people with a type of leukemia (AML) that has a FLT3 gene change, which makes the cancer grow faster. After a stem cell transplant, some patients took the drug gilteritinib in earlier trials, while others received standard care. Researchers compared medical r…

This study enrolled 349 people with myelodysplastic syndromes (MDS) to see how certain gene mutations affect survival. Researchers collected blood samples at diagnosis and tracked patients over time. The goal was to understand which mutations are linked to better or worse outcome…

This completed study looked at 98 adults with acute myeloid leukemia (AML) in first remission who received a stem cell transplant from a matched sibling, matched unrelated, or half-matched family donor. All patients got the same chemotherapy conditioning before transplant. Resear…

This completed Phase 1 study gave 6 healthy Chinese men a single dose of the leukemia drug TGRX-678 to see how the body absorbs, breaks down, and gets rid of it. Researchers measured radioactivity in blood, urine, and stool to map the drug's path. No treatment was given—just unde…

This study analyzed insurance claims from over 2,500 people with chronic myeloid leukemia (CML) to see how often side effects from tyrosine kinase inhibitors (TKIs) occur and how they affect treatment changes and healthcare costs. Researchers looked at side effects that required …

This study looked at how 754 people with chronic myeloid leukemia (CML) in Japan were treated with drugs called tyrosine kinase inhibitors (TKIs) between 2011 and 2019. Researchers used a hospital database to track which TKIs patients received, how often they switched or stopped …

This completed study involved 146 patients with blood cancers who received a stem cell transplant from a donor. Researchers collected blood and tissue samples over a year to study immune cells linked to graft-versus-host disease (GVHD), a common complication where donor cells att…